Redmile Group LLC Increases Stock Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Redmile Group LLC increased its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 22.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 320,149 shares of the company’s stock after purchasing an additional 58,346 shares during the period. Establishment Labs makes up 1.0% of Redmile Group LLC’s investment portfolio, making the stock its 28th largest holding. Redmile Group LLC’s holdings in Establishment Labs were worth $14,749,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. purchased a new stake in Establishment Labs during the 4th quarter valued at $12,898,000. Raymond James Financial Inc. purchased a new stake in Establishment Labs during the fourth quarter valued at $5,494,000. Swiss National Bank lifted its holdings in Establishment Labs by 2.7% in the fourth quarter. Swiss National Bank now owns 38,500 shares of the company’s stock valued at $1,774,000 after acquiring an additional 1,000 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Establishment Labs in the fourth quarter worth about $161,000. Finally, Sei Investments Co. increased its holdings in Establishment Labs by 22.3% during the fourth quarter. Sei Investments Co. now owns 42,471 shares of the company’s stock valued at $1,957,000 after buying an additional 7,731 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Price Performance

ESTA stock opened at $36.46 on Thursday. The company has a market capitalization of $1.05 billion, a PE ratio of -14.13 and a beta of 0.73. The company’s fifty day moving average price is $34.40 and its 200-day moving average price is $38.37. Establishment Labs Holdings Inc. has a one year low of $26.56 and a one year high of $60.12. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.13. The firm had revenue of $41.38 million during the quarter, compared to analyst estimates of $41.15 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.58) earnings per share. On average, equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ESTA has been the subject of a number of recent research reports. Stephens reiterated an “overweight” rating and set a $52.00 price objective on shares of Establishment Labs in a research note on Thursday, March 6th. Needham & Company LLC upgraded shares of Establishment Labs from a “hold” rating to a “buy” rating and set a $48.00 price objective on the stock in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.83.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.